Roche Holding $ROCHE

Recent News (15)

• Simcere Zaiming Enters Exclusive License Agreement with Roche for SIM0660 Global Development PR Newswire · 01 Sep 2026 NANJING, China, Sept. 1, 2026 /PRNewswire/ -- Simcere Zaiming, a subsidiary of Simcere Pharmaceutical Group (2096.HK) today announced that it has entered into an exclusive global licensing agreement w…
• Formosa Pharmaceuticals Files Clinical Trial Application for TSY-110, an Antibody-Drug Conjugate Biosimilar Targeting HER2-Positive Breast Cancers PR Newswire · 28 Aug 2026 TSY-110 is positioned to become the first biosimilar alternative to Roche's Kadcyla® (ado-trastuzumab emtansine) in major regulated markets. TAIPEI, Aug. 28, 2026 /PRNewswire/ -- Formosa Pharmaceutica…
• Roche’s Vabysmo demonstrates sustained two-year results in a difficult-to-treat form of neovascular age-related macular degeneration (nAMD) GlobeNewswire · 28 Aug 2026 Basel, 28 August 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today new two-year data from the Phase IIIb/IV SALWEEN study of Vabysmo® (faricimab), presented at the 19th Asia-Pacific Vitreo-ret…
• Roche receives FDA approval for HER2 tests in gastric cancers Investing.com · 26 Aug 2026 Roche receives FDA approval for HER2 tests in gastric cancers
• Roche receives FDA approval for companion diagnostic tests to identify patients with HER2-positive metastatic gastroesophageal adenocarcinoma eligible for ZIIHERA PR Newswire · 26 Aug 2026 The PATHWAY HER2 (4B5) test and VENTANA HER2 Dual ISH DNA Probe Cocktail help identify HER2-positive metastatic gastric, gastroesophageal junction and esophageal adenocarcinoma. Differential diagnosis…
• Top Stock Reports for Berkshire Hathaway, Roche & RTX Zacks Investment Research · 25 Aug 2026 Top Stock Reports for Berkshire Hathaway, Roche & RTX  Zacks Investment Research
• FDA approves new blood test for Alzheimer’s disease The Hill · 24 Aug 2026 The Food and Drug Administration (FDA) has granted approval for a new test for Alzheimer's disease, marking the fourth time such a blood test has been approved in less than two years. Roche announced …
• Quest Diagnostics to Offer FDA-Cleared Roche pTau217 Blood Test to Assess Alzheimer's Disease Pathology PR Newswire · 24 Aug 2026 Test to join the company's expansive portfolio of Quest AD-Detect® blood tests for assessing symptomatic patients Quest also launching a new multi-biomarker AD-Detect® lab-developed blood test with lo…
• Roche receives FDA clearance for Elecsys® pTau217, advancing Alzheimer's disease assessment across primary and specialty care PR Newswire · 24 Aug 2026 First and only FDA-cleared, single-biomarker blood test supporting both rule-in and rule-out assessment of amyloid pathology across primary and specialty care settings The test delivers consistency ac…
• Roche’s US subsidiary Genentech announces manufacturing expansion in the United States GlobeNewswire · 20 Aug 2026 Basel, 20 August 2026 - Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY) today announced plans to invest approximately $750 million in a new device fill-finish manufacturing facilit…
• Roche announces partnership with Ivy Tech to help strengthen Indiana's medical laboratory workforce PR Newswire · 30 Jul 2026 Strategic collaboration between Roche Diagnostics and Ivy Tech Community College addresses critical workforce shortages in Indiana's medical laboratory sector through a phased development framework. P…
• Roche receives FDA clearance for the cobas® BV/CV assay, enabling fast and highly accurate vaginitis diagnosis PR Newswire · 24 Jul 2026 The new PCR test uses clinician-collected or clinician-instructed, self-collected vaginal swab specimens to simultaneously detect organisms associated with Bacterial vaginosis (BV) and Candida vaginit…
• CHMP recommends EU approval of Roche’s Susvimo, the first continuous delivery treatment for neovascular age-related macular degeneration (nAMD) GlobeNewswire · 24 Jul 2026 Basel, 24 July 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Susv…
• [Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong momentum continues in the first half of 2026, delivering +6% sales growth at constant exchange rates; -2% in CHF due to the significant appreciation of the Swiss franc GlobeNewswire · 23 Jul 2026 Outlook for 2026 Roche (SIX: RO, ROP; OTCQX: RHHBY) expects an increase in Group sales in the mid single digit range (CER) for 2026. Core earnings per share are targeted to develop in the high single …
• Nurix Therapeutics Announces HSR Clearance of Global Collaboration with Roche to Co-Develop and Co-Commercialize Potential Best-in-Class BTK Degrader Bexobrutideg Across Malignant Hematology, Immunology and Neurology GlobeNewswire · 21 Jul 2026 BRISBANE, Calif., July 21, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of…